Business Context and Reporting Period
Senti Biosciences, Inc. (SNTI) filed a Current Report on Form 8-K on September 27, 2024, regarding an event that occurred on September 23, 2024. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in South San Francisco, California.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a specific material agreement.
Material Changes and Agreements
On September 23, 2024, the Company entered into a sublease agreement as the sublandlord with BKPBIOTECH, Inc. and JLSA2 Therapeutics, Inc. (collectively, the "Subtenant"). Key terms include:
- Property: Approximately 7,247 rentable square feet at the Company's corporate headquarters (Two Corporate Drive, South San Francisco, CA).
- Term: Estimated effective date of October 1, 2024, expiring April 30, 2027, subject to landlord consent and earlier termination.
- Rent Structure:
- Year 1: $35,147.95 per month.
- Year 2: $36,378.13 per month.
- Year 3: $37,651.36 per month.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of general risks. The agreement is subject to customary events of default, representations, warranties, and covenants. The full text of the Sublease is expected to be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2024.
Investor Verification Checklist
- Verify the receipt of landlord consent from Britannia Biotech Gateway Limited Partnership to confirm the sublease effective date.
- Review the full Sublease agreement in the upcoming Form 10-Q for specific termination clauses and default conditions.
- Assess the impact of the new rental income on the Company's operating cash flow in future periods.